Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab.
JACC Basic Transl Sci
; 5(6): 549-557, 2020 Jun.
Article
en En
| MEDLINE
| ID: mdl-32613143
3D, 3-dimensional; AU, arbitrary unit; BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay; FCR, fractional catabolic rate; FRG, Fah(−/−)Rag2(−/−)Il2rg(−/−); HoFH, homozygous familial hypercholesterolemia; LC-MS/MS, liquid chromatography tandem mass spectrometry; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; Lp(a), lipoprotein(a); MFI, mean fluorescence intensity; PBMC, peripheral blood mononuclear cell; PBS, phosphate-buffered saline; PCSK9, proprotein convertase subtilisin/kexin type 9; apoB100, apolipoprotein B100; bodipy, boron dipyrromethene; lipoprotein(a); liver-humanized mice; low-density lipoprotein receptor; proprotein convertase subtilisin/kexin type 9; rPCSK9, recombinant proprotein convertase subtilisin/kexin type 9
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
JACC Basic Transl Sci
Año:
2020
Tipo del documento:
Article
País de afiliación:
Francia
Pais de publicación:
Estados Unidos